Ottima azienda solida finanziariamente senza debiti a lungo e breve termine. Il FcF tende a diminuire nel tempo mentre aumentano i compensi per i vari membri del board che hanno uno skill in the game moderato.Read more
Corcept Therapeutics could grow beyond its current lead drug as more doctors test for high cortisol problems and as a new medicine moves closer to approval in multiple diseases. But the story hinges on winning key legal and regulatory battles and holding up against pricing pressure while the company scales up how it serves patients.Read more
Corcept is betting that blocking cortisol can unlock new treatments across hormone disorders and several hard-to-treat cancers, with a key medicine nearing a major regulator decision. The catch is that supply hiccups, trial results, and the risk of cheaper copycat competition could slow the payoff even if the science keeps moving forward.Read more
Catalysts About Corcept Therapeutics Corcept Therapeutics develops selective cortisol modulators to treat serious endocrine, metabolic and oncologic diseases. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
